IPP Bureau

U.S. FDA gives green light to Moderna and J&J booster doses
U.S. FDA gives green light to Moderna and J&J booster doses

By IPP Bureau - October 21, 2021

The authority also allowed mix and match of booster doses once the primary vaccine has been administered.

Ivenix selects Eastman Tritan copolyester for its new infusion system
Ivenix selects Eastman Tritan copolyester for its new infusion system

By IPP Bureau - October 21, 2021

Ivenix selected Tritan MXF for the pump exterior because of its excellent chemical resistance and durability in the face of the aggressive disinfection protocols needed to prevent the spread of healthcare-associated infections

Syngene revenue from operations up 17 per cent in Q2FY22
Syngene revenue from operations up 17 per cent in Q2FY22

By IPP Bureau - October 21, 2021

The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations

Biocon Biologics’ interchangeable biosimilar insulin Glargine preferred on Express Scripts
Biocon Biologics’ interchangeable biosimilar insulin Glargine preferred on Express Scripts

By IPP Bureau - October 21, 2021

Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)

HCL Tech and Innovaccer collaborate to scale up digital health transformation
HCL Tech and Innovaccer collaborate to scale up digital health transformation

By IPP Bureau - October 20, 2021

By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance

Medtronic announces launch of Open Innovation Platform for APAC
Medtronic announces launch of Open Innovation Platform for APAC

By IPP Bureau - October 20, 2021

The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology

FDA approves Cyltezo, the first interchangeable biosimilar to Humira
FDA approves Cyltezo, the first interchangeable biosimilar to Humira

By IPP Bureau - October 20, 2021

Second interchangeable biosimilar product approved by agency

NIH grants in-principle accreditation to Advanced Enzymes supplements
NIH grants in-principle accreditation to Advanced Enzymes supplements

By IPP Bureau - October 20, 2021

The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness

AstraZeneca India opens clinical data and insights division
AstraZeneca India opens clinical data and insights division

By IPP Bureau - October 20, 2021

The division is expected to grow to over a 100-member strong team by 2022

Trivitron partners with Diagon-Vanguard to launch its coagulation range in India
Trivitron partners with Diagon-Vanguard to launch its coagulation range in India

By IPP Bureau - October 20, 2021

The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary

Domestic growth to the fore as US weakness persists: ICICI Direct
Domestic growth to the fore as US weakness persists: ICICI Direct

By IPP Bureau - October 19, 2021

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report

U.S. FDA authorises new saliva sample collection for Covid-19
U.S. FDA authorises new saliva sample collection for Covid-19

By IPP Bureau - October 19, 2021

The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day

Pharma exports continue to climb in H1FY22
Pharma exports continue to climb in H1FY22

By IPP Bureau - October 19, 2021

Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.

Alcon announces launch of AcrySof IQ Vivity in India,
Alcon announces launch of AcrySof IQ Vivity in India,

By IPP Bureau - October 19, 2021

It is the first presbyopia-correcting lens implant for cataract surgery

Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules

By IPP Bureau - October 19, 2021

The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg

Latest Stories

Interviews

Packaging